Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19

COVID-19 pandemic continues to evolve and new variants like Delta and Omicron have been discovered. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2 which received emergency use authorisation for treatment and post-exposure prophylaxis in patients with high ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Dipankar, Clifford, Stephanie A., Fricker, Frederick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304944/
https://www.ncbi.nlm.nih.gov/pubmed/35798332
http://dx.doi.org/10.1017/S1047951122002190
_version_ 1784752205885079552
author Gupta, Dipankar
Clifford, Stephanie A.
Fricker, Frederick J.
author_facet Gupta, Dipankar
Clifford, Stephanie A.
Fricker, Frederick J.
author_sort Gupta, Dipankar
collection PubMed
description COVID-19 pandemic continues to evolve and new variants like Delta and Omicron have been discovered. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2 which received emergency use authorisation for treatment and post-exposure prophylaxis in patients with high risk of progression to severe disease. We review our experience with use of REGEN-COV in paediatric heart transplant patients.
format Online
Article
Text
id pubmed-9304944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-93049442022-07-27 Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19 Gupta, Dipankar Clifford, Stephanie A. Fricker, Frederick J. Cardiol Young Brief Report COVID-19 pandemic continues to evolve and new variants like Delta and Omicron have been discovered. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2 which received emergency use authorisation for treatment and post-exposure prophylaxis in patients with high risk of progression to severe disease. We review our experience with use of REGEN-COV in paediatric heart transplant patients. Cambridge University Press 2022-07-07 /pmc/articles/PMC9304944/ /pubmed/35798332 http://dx.doi.org/10.1017/S1047951122002190 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Brief Report
Gupta, Dipankar
Clifford, Stephanie A.
Fricker, Frederick J.
Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19
title Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19
title_full Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19
title_fullStr Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19
title_full_unstemmed Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19
title_short Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19
title_sort use of regen-cov in children after heart transplantation for treatment and post-exposure prophylaxis of covid-19
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304944/
https://www.ncbi.nlm.nih.gov/pubmed/35798332
http://dx.doi.org/10.1017/S1047951122002190
work_keys_str_mv AT guptadipankar useofregencovinchildrenafterhearttransplantationfortreatmentandpostexposureprophylaxisofcovid19
AT cliffordstephaniea useofregencovinchildrenafterhearttransplantationfortreatmentandpostexposureprophylaxisofcovid19
AT frickerfrederickj useofregencovinchildrenafterhearttransplantationfortreatmentandpostexposureprophylaxisofcovid19

Ejemplares similares